Top Analyst Upgrades and Downgrades (BIIB, FRX, GENZ, GILD, HOLX, LVS, MOS, NVAX, RIG, TXT)
These are the top ten analyst research initiations, upgrades, and downgrades we have seen from top Wall Street firms early this Wednesday morning: Biogen-Idec (BIIB) Started as Underperform at BofA/Merrill Lynch. Forest Labs (FRX) Cut to Hold at Needham. Genzyme…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
These are the top ten analyst research initiations, upgrades, and downgrades we have seen from top Wall Street firms early this Wednesday morning:
Biogen-Idec (BIIB) Started as Underperform at BofA/Merrill Lynch.
Forest Labs (FRX) Cut to Hold at Needham.
Genzyme (GENZ) Started as Buy at BofA/Merrill Lynch.
Gilead (GILD) Started as Buy at BofA/Merrill Lynch.
Hologic (HOLX) Cut to Hold at Canaccord.
Las Vegas Sands (LVS) Raised to Buy at Argus.
Mosaic (MOS) Started as Sector Perform at CIBC.
Novavax (NVAX) Cut to Market Perform at Rodman & Renshaw.
Transocean (RIG) Started as Outperform at BMO Capital.
Textron (TXT) Raised to Conviction Buy List at Goldman Sachs.
JON C. OGG
Contact [email protected] for any questions or corrections.